Alzheimer’s Disease :: Uncertainty remains for newly diagnosed patients with mild Alzheimer’s disease

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the global specialty biopharmaceutical company welcomes the decision of Judge Linda Dobbs in the Judicial Review that the National Institute for Health and Clinical Excellence (NICE) Appraisal Committee acted unlawfully by not having due regard to anti-discriminatory legislation in the formulation of their Guidance, potentially resulting in discrimination against mild patients with learning or language difficulties.

However, Shire is disappointed that the judgement in effect upholds the NICE Guidance that the majority of newly diagnosed patients with Alzheimer?s disease of mild severity should not receive drug treatments on the NHS.

NICE have been directed to prepare revised Guidance to address this issue. Until the wording of the NICE Guidance is reviewed and agreed that it has met the Judge?s directions, the practical effect of such revised guidance for clinicians and patients remains uncertain.


Leave a Comment